COMMUNIQUÉS West-GlobeNewswire

Aveanna Healthcare Announces Successful Debt Repricing
28/05/2026
ATLANTA, May 28, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH), a leading, diversified home care platform focusing on providing care to medically complex, high-cost patient [...]
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
28/05/2026
SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with [...]
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
28/05/2026
ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor [...]
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
28/05/2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
28/05/2026
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
28/05/2026
Auto-renewing Master Services Agreement engages Biomerica’s integrated development and manufacturing platform, reflecting the Company’s CDMO strategy as a capital-efficient, parallel revenue stream alongside its core [...]
Groundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJM
28/05/2026
Repairon Announces Publication of Clinical Trial Results for Engineered Human Heart Muscle Tissue in the New England Journal of Medicine GÖTTINGEN, Germany and PROVIDENCE, R.I., May 28, 2026 (GLOBE NEWSWIRE) -- Repairon [...]
Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
28/05/2026
BASEL, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
28/05/2026
Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation [...]
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
28/05/2026
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
28/05/2026
Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize Manufacturing capacity more than triples, with initial capacity to support over 17,000 users Volume manufacturing [...]
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
28/05/2026
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stroma-rich tumours US trial (OCTOPOD-IP) is exploring [...]
XL‑protein Launches Spin-Off PASylANTA Therapeutics to Develop Long‑Acting IL‑1Ra Biobetters
28/05/2026
Freising, Germany, May 28, 2026 (GLOBE NEWSWIRE) -- XL‑protein GmbH today announced the launch of PASylANTA Therapeutics GmbH , a new Germany-based biotechnology company focused on the development of long‑acting IL‑1 [...]
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
28/05/2026
Orphan Drug Designation confers regulatory, financial and strategic advantages EO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patients EO2463 has shown complementary [...]
Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
28/05/2026
Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3 Paris, le 28 mai 2026. L’Agence américaine des produits alimentaires et médicamenteux ( [...]
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
28/05/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]
De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.
28/05/2026
Les données concernant IQIRVO ® viennent enrichir les connaissances scientifiques sur la fatigue, en montrant des améliorations cliniquement significatives chez des patients présentant une fatigue modérée à sévère à l’ [...]
argenx to Host Myositis R&D Webinar on June 23, 2026
28/05/2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will [...]
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
28/05/2026
IQIRVO ® data expands scientific evidence in fatigue, showing clinically meaningful improvements in patients with moderate-to-severe fatigue at baseline In the first real-world analysis in patients with PBC and an ALP 1 [...]

Pages